Calutide
Calutide (Bicalutamide 50 mg) — Cipla non-steroidal anti-androgen for advanced prostate cancer. Combined with LHRH agonist for combined androgen blockade. Hepatotoxicity monitoring.
✓ Medicinsk gennemgået af Morgan Ellis — Apoteksforsker · 8 års erfaring · Sidst gennemgået: maj 2026
Hurtigt svar
Calutide — Bicalutamide 50 mg (Cipla Inc). Non-steroidal androgen receptor antagonist for advanced prostate cancer — usually combined with LHRH agonist/antagonist for combined androgen blockade, or as monotherapy in selected cases.
Hvad du får med MedsBase:
- WHO-GMP certificeret producent
- Diskret kuvertemballage uden mærkning
- Levering til hele verden
- Bedømt af 1.400+ kunder (læs anmeldelser)
📦 Genforsendelsesgaranti: hvis din ordre ikke er ankommet inden for 20 hverdage efter afsendelse, genforsender vi den uden ekstra omkostninger. Læs politikken.
Hvorfor bestille fra MedsBase
Calutide ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.
Bicalutamide can cause severe hepatic injury. Baseline LFTs; recheck at 1 month and every 3 months in the first year. Stop immediately if jaundice, dark urine, or pruritus develops or LFTs >2.5× ULN.
Ofte stillede spørgsmål
When is this used?
Non-steroidal androgen receptor antagonist for advanced prostate cancer — usually combined with LHRH agonist/antagonist for combined androgen blockade, or as monotherapy in selected cases.
Side effects to watch?
Hot flushes, gynaecomastia, fatigue, sexual dysfunction (anti-androgen class effect). Drug-specific monitoring as outlined in the safety boxes above.
Lægemiddelinteraktioner?
Vary by molecule — abiraterone is CYP3A4 substrate; bicalutamide is CYP3A4 substrate. Always disclose all medications. Strong CYP3A4 inhibitors/inducers significantly affect levels.
Hvornår bør det stoppes?
On disease progression, intolerable toxicity, or successful response with planned treatment break. Always specialist-decided — abrupt cessation can result in transient PSA rise (withdrawal response) which is generally not concerning.
PSA monitoring?
PSA every 1-3 months while on therapy. Rising PSA on castration suggests castration-resistance — may need switch to second-line agents (abiraterone, enzalutamide, docetaxel).
Combined androgen blockade?
LHRH agonist (goserelin, leuprolide) + bicalutamide is a common combination. Maximal androgen blockade has modest survival benefit over LHRH alone.
Bone health?
Long-term androgen deprivation accelerates bone loss. Add a bisphosphonate (zoledronic acid) or denosumab in osteopenia/osteoporosis. Calcium and vitamin D supplementation.
Graviditet?
Anti-androgens are teratogenic — partners must use effective contraception during therapy. Most relevant for younger men with localised disease.
Hvad hvis jeg glemmer en dosis?
Take when you remember if same day; otherwise skip. Specialist may have specific guidance for missed doses depending on regimen.
Cardiovascular monitoring?
Mandatory for fosfestrol; advised for abiraterone (BP, fluid retention, electrolytes); routine for bicalutamide (occasional CV review).
Other Cancer & Anti-Androgen Therapy
- Calutide — bicalutamide 50 mg — alternative anti-androgen brand
- Xbira — abiraterone 250 mg — CYP17 inhibitor for mCRPC
- Honvan — fosfestrol 120 mg — diethylstilbestrol diphosphate
- Estramustine — estramustine phosphate — alkylator for hormone-refractory disease
- Zoldria — zoledronic acid IV for bone metastases
More options in Anti Cancer Medication
Rangeret efter seneste MedsBase ordrevolumen — hvad andre kunder i denne kategori vælger.
| Styrke | 50 mg |
|---|---|
| Antal | 30 tablet(ter), 60 tablet(ter), 90 tablet(ter) |
| Farmaceutisk form | Tablet/s |
| Producent | Cipla Inc |
| Behandling | Prostate Cancer |
| Generisk mærke | Bicalutamide |
Calutide
Spørgsmål & svar
Calutide
Relaterede produkter
Anmeldelser
Der er ingen anmeldelser endnu